IE58228B1 - Novel 8 alpha -acylaminoergolines - Google Patents

Novel 8 alpha -acylaminoergolines

Info

Publication number
IE58228B1
IE58228B1 IE6485A IE6485A IE58228B1 IE 58228 B1 IE58228 B1 IE 58228B1 IE 6485 A IE6485 A IE 6485A IE 6485 A IE6485 A IE 6485A IE 58228 B1 IE58228 B1 IE 58228B1
Authority
IE
Ireland
Prior art keywords
compound
hydrogen
formula
acid addition
addition salt
Prior art date
Application number
IE6485A
Other versions
IE850064L (en
Original Assignee
Sandoz Limited A Swiss Body Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Limited A Swiss Body Co filed Critical Sandoz Limited A Swiss Body Co
Priority to IE358789A priority Critical patent/IE58241B1/en
Priority to IE358689A priority patent/IE58240B1/en
Publication of IE850064L publication Critical patent/IE850064L/en
Publication of IE58228B1 publication Critical patent/IE58228B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/10—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hetero atoms directly attached in position 8
    • C07D457/12—Nitrogen atoms

Abstract

Compounds of the formula I (I) wherein R1 is hydrogen or C1-4alkyl, R2 is hydrogen, chlorine, bromine or methyl, R3 is C1-5alkyl or C3-5alkenyl and R4 is C3-7alkyl; C3-7cycloalkyl; adamantyl; or optionally substituted phenyl, having valuable pharmaceutical, and in particular LH- and PRL-secretion inhibiting as well as neuroleptic activity.

Description

The present invention relates to novel 8a-acyl amino-ergolines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals.
The 8a-ergolines comprises a major class of compounds possessing varying degrees and type of biological activity and potential therapeutic utility. Thus DOS 25 30 577 and 26 56 344 disclose a wide range of ergoline derivatives which are variously 8a-substituted. Amongst possible 8a-substituents embraced there are included numerous derivatised amino groupings including inter al. acylamino and related residues. The subject compounds are variously described as possessing dopaminergic and prolactin secretion inhibiting activity.
The present invention provides a novel group of 8a-acylamino ergolines, which have been found to possess especially interesting or advantageous biological activity or profile.
More particularly the present invention relates to compounds of formula I wherein Rl is hydrogen or Ci-4alkyl, R2 is hydrogen, chlorine, bromine or methyl, R3 is Ci-5alkyl or C3_salkenyl in which the double bond is not at the carbon atom adjacent to the nitrogen atom, and R4 is C3-7alkyl; C3-7Cycloalkyl; adamantyl; phenyl; phenyl substituted by one or more members selected from the group consisting of Cl-3alkyl, Ci-3alkoxy, Ci-3alkylthio, trifluoromethyl, hydroxy, nitro, amino and mono- and di-(Ci.3-alkyl)-amino; or phenyl bearing a condensed, non-aromatic, heterocyclic ring having 5- or 6-ring members including 1 or 2 hetero atoms selected from the group consisting of oxygen and sulphur, with the proviso that i) when 1½ and Rj are both hydrogen and Rj is methyl, R« is other than t.butyl and ii) when Rx is hydrogen, R2 is chlorine or methyl and Rj is methyl, R< is other than t.butyl, as veil as the acid addition salts thereof.
A preferred group of formula I are those of formula la wherein I5 Rl and R2 have the meanings given for formula I, R3a is C2-5alkyl or C3_5alkenyl in which the double bond is not at the carbon atom adjacent to the nitrogen atom, and R4a is (i) C3_7alkyl or C3-7cycloalkyl; or (ii) phenyl; phenyl substituted by one or two members selected from the group 20 consisting of Ci_2alkyl, Ci-2alkoxy, Ci-2alkylthio, hydroxy and nitro; or phenyl substituted at two adjacent carbon atoms by a divalent residue of formula -O-CH2-O- or -Z-(CH2)n> wherein Z is oxygen or sulphur and n is 2 or 3.
A further preferred group of compounds of formula I are those of formula lb -4wherein Rl has the meaning given for formula I, R2& is chlorine, bromine or methyl, and R«b is C3_7alkyl, C3_7cycloalkyl or admantyl, with the proviso that when R3 is hydrogen, R2b is chlorine or methyl, R«b is other than t.butyl.
Alkyl groups and moieties in the compounds of formulae I, I a or lb may be straight- or branched-chain.
For the above formula Ia, the following significances, as well as combinations, thereof are preferred: 1. Ri is hydrogen or methyl, especially hydrogen. 2. R2 is hydrogen. 3. R3a is C3_salkyl, especially n-propyl. 4. R4a is as previously defined under (ii): R4a is especially: phenyl; phenyl substituted by one or two members selected from the group consisting of methyl, methoxy, methylthio, hydroxy and nitro; phenyl substituted at two adjacent carbon atoms by the divalent residue of formula -O-CH2-O-; or 2,3-dihydrobenzofury1-5.
For the above formula lb, the following significances, as well as combinations thereof, are preferred: 1. Ri is hydrogen or methyl, especially hydrogen. 2. R4b is C3-7alkyl, especially branched-chain C3-7alkyh In particular branched-chain C3_sa1ky1, most preferably t.butyl. -5In one group of compounds of formula I, R4 is C3-7alkyl; C3_7cycloalkyl; adamantyl; phenyl; phenyl substituted by one or two members selected from the group consisting of Ci_3alkyl, Ci_3alkoxy, Ci-3alkylthio, hydroxy, amino and mono- and di-(Ci_3alkyl)-amino; or phenyl substituted at two adjacent carbon atoms by a divalent residue of formula -O-CH2-O- or -Z-(CH2)n-, wherein Z is oxygen or sulphur and n is 2 or 3.
In one group of compounds of formula Ia, R4® is (i) C3_7a1kyl or Ίθ C3_7cycloalkyl; or (ii) phenyl; phenyl substituted by one or two members selected from the group consisting of C}_2alkyl, Ci-2alkoxy, Ci-2alkylthio and hydroxy; or phenyl substituted at two adjacent carbon atoms by a divalent residue of formula -O-CH2-O- or -Z-(CH2)n wherein Z is oxygen or sulphur and n is 2 or 3.
The present invention also provides a process for the production of the compounds of formula I and their acid addition salts, which process comprises: a) reacting a compound of formula II N R - NH n-r3 H (II) -6wherein R^, Rg and R3 have the meanings given above with a compound of formula III R4-COOH (III) wherein R4 has the meaning given above, or a reactive functional derivative thereof; b) Chlorinating or brominating a compound of formula I wherein R2 is hydrogen to produce the corresponding compound of formula I wherein R2 is chlorine or bromine; or c) N-(Ci_4alkylating) a compound of formula I wherein Ri is hydrogen to produce a corresponding compound of formula I wherein Ri is Ci-4alkyl; and recovering the obtained compound of formula I as such or as an acid addition salt thereof.
Process step a) may be carried out in accordance with standard procedures. Suitable reactive functional derivatives of the compounds of formula III include e.g. the corresponding acyl halides, in particular chlorides, and imidazolides. Reaction with acylhalldes is suitably effected in the presence of a base, such as triethylamine or HGnig-base. Reaction with imidazolides (obtained e.g. by reaction of the compound of formula III with Ν,Ν-carbonyldiimidazole) is suitably carried out in an inert solvent such as tetrahydrofuran or ethanol, e.g. at reflux temperature. Where a compound of formula I is employed as such, reaction may suitably be effected e.g. 1n the presence of propanephosphonic acid anhydride. -7Process step b) may also be carried out in accordance with known techniques, using standard chlorinating or brominating agents such as N-Br- or N-Cl-succinimide, sulphuryl chloride or pyrrolidonehydrobromideperbromide. The reaction is conveniently performed in the presence of an inert diluent or solvent such as methylene chloride or tetrahydrofuran.
Process step c) may be carried out in accordance with known methods for the N-alkylation of indolines, e.g. employing a compound of formula IV Rp-X (IV) wherein is Ci-4alkyl and X is a leaving group, e.g. a halogen atom, in particular chlorine, fluorine or bromine atom, or methane- or p-toluene-sulfonyloxy group. The reaction is suitably carried out in the presence of an inert solvent or diluent such as dimethylsulfoxide, preferably 1n the presence of an acid binding agonist such as KOH.
The starting materials of formula II are known or may be produced analogously to the known compounds and in accordance with known procedures. The starting materials for steps b) and c) may be prepared in accordance with process step a).
The compounds of formula I may be recovered from the initially obtained reaction medium as such (i.e. 1n free base form) or in acid addition salt form e.g. in the form of their pharmaceutically acceptable acid addition salts. Suitable pharmaceutically acceptable acid addition salts include both such salts with inorganic acids, for example the hydrochloride salts, as well as such salts with organic acids, for example the oxalates and maleates. -8The following examples are illustrative of the processes for the production of the subject compounds: -9EXAMPLE 1: Preparation of 8a-benzoylamino-6-n-propylergoline 1.4 ml benzoylchloride in 5 ml CH2CI2 are added drop-wise with stirring at 5 - 10 * C to a suspension of 3.0 g 8a-amino-6-npropylergoline in 100 ml CH2CI2 and 2.0 ml triethylamine. The obtained reaction mixture is stirred for 15 to 20 hours at 20 * C and then washed thoroughly 2 x with 25 ml 2N NaOH and H2O. The organic phase is dried over MgS04, filtered and evaporated. The residue (pale brown foam) is dissolved in ethanol, and crystallised as the hydrobromide by addition of equivalent amounts of HBr in acetic acid. M.P. on recrystallisation from C2H5OH/H2O (80 ’· 2) 3 290 * with decomposition.
The following compounds of formula I in which Rl 3 hydrogen are obtained analogously: EXAMPLE R2 R3 r4 M.P. * C (form) 2 H -(CH2)2-CH3 -C(CH3)3 328-330’ (Hydrochloride) 3 H -(CH2)2-CH3 Adamantyl-1 from 265 * (Base) 4 H -(CH2)2-CH3 -C(CH3)2-C2H5 129 ’ (Base) 5 H -CH(CH3)2 -C(CH3)3 from 120 * (Base) 6 H -(CH2)2-CH3 208-211’ (Mesylate) EXAMPLE «2 R3 r4 M.P. * C (form) 7 Η -(CH2)2-CH3H3CT-\ Base. 8 Η -(CH2)2-CH3 Tgo Compounds obtained as 0 an amorphous 9 Η -(CH2)2-CH3 V ^powder for characterisation see NMR data following. sch3 10 Η -(CH2)2-CH3 OH 11 Η -(CH2)2-CH3 A © © 235-237* (Hydrochloride) 12 Η -(CH2)2-CH3 0CH3 188-190* (Base) 13 Η -(CH2)2-CH3 253-255* (1 Citrate) 14 Η -(CH2)2’CH3 212-214*(i Fumarate) -η- EXAMPLE R2 R3 r4 M.P. ’ C (form) 15 H -(CH2>2-CH3 N02 230-233° (Hydrochloride) 16 H -(CH2)2-CH3 '—<0CH3 184-186° (Oxalate) 17 H -(CH2)2CH3 /O\CH3 '—<0H 220-225° (Oxalate) 18 H -(CH2)2CH3 /OVOCH3 X—C'C2H5 from 110* (Base) 19 ch3 ch3 8ase. Amorphous powder. See NMR data ch30 following. 20 CH3 ch3 201-202° (Base) 21 CH3 CH3 -CH(CH3)2 200-204° (Base) 22 ch3 ch3 -C(CH3)2-C2H5 210-212° (Base) 23 CH3 CH3 Adamantyl-1 from 250’ (Base) EXAMPLE R2 R3 R4 M.P. * G (form) 24 CH3 -(CH2)2CH3 (°) _i 8ase. Amorphous powder. See NMR data following. 25 ch3 -(CH2)2CH3 -C(CH3)3 211-212* (Base) 26 H CH3 Adamantyl-1 >290* (Base) 27 H CH3 -C(CH3)2-C2H5 153* (Base) 28 H ch3 <2> 228-230* (Base) 29 H CH3 -CH(CH3)2 170-171* (Base) The starting material required for the preparation of the compounds of examples 19 to 23, namely 8a-ami no-2,5-dimethy1ergoline, may be prepared as follows: a) ?Γ®Β2ϋ25ΐ22-2£-?ζ'525!ϊ^1ζ2*Ι9ζ2!!3ϊ9!Ζ2ΐ^52ϋ9ΐ2_a2i9-TS£!!¥l ester g 2|-methyl-lysergic acid in 350 ml H2O and 12.4 ml triethylamine are hydrogenated under normal pressure and at room temperature employing 5 % Pd/C. After up-take of the calculated amount of H2, the reaction mixture is filtered -13over Hyflo concentrated to half volume and adjusted to pH 6 by addition of IN HCl. The obtained crystalline product is filtered off, dried, taken up in CH3OH/HC1 and the obtained suspension stirred at room temperature for 2-3 days until full conversion as determined by thin-layer chromatography. The product is evaporated and subjected to distribution between sodium carbonate and ethyl acetate. After drying and evaporating the title compound is obtained as crystals, which are then rubbed with ethyl ether. M.P. a 180 - 182 * C. b) pCS2*C2bi22_2L?zT?bb¥lz2ii9zdit!^r2isgly§ergic_asid_m§it]yl ester 43.4 ml of 1.65 molar butyllithium are added at - 50 * C under argon to 200 ml tetrahydrofuran and 10.7 ml diisopropylamine. 9.5 g of the product of step a) in 100 ml tetrahydrofuran are added drop-wise after 30 mins. After allowing to stand for 1 hour at - 20 * C the pH is adjusted to 7 by the addition of 10 % HCl. The mixture is warmed to room temperature, and the organic phase separated and washed 2 x with saturated brine. The title compound is obtained after drying and evaporation, filtration of the obtained oil using silica gel and CH2Cl2/Me0H (98 : 2) as eluant and crystallisation from Isopropanol. M.P. = 174 - 176 ’ C. c) p Γ?22!Ζ2ϊί22_2ί _?ζΤ2ϊ?!ϊ1ζ2*19ζ^ί!!ϊ^ϋ2ΐϊ52Γ9ί£_32ΐ^-!!ϊ^Γ2? 1-2 .95 g hydrazine hydrochloride and 6.8 ml hydrazine hydrate are added to 8.5 g of the product of step b) in 250 ml n-propanol and the obtained reaction mixture heated under reflux. The product is concentrated to half valume, filtered -14and washed with H2O and filtered by suction to yield the title compound. M.P. = 250 * C with decomposition. d) Pr?PaC2tion_of_8oHamino-246;dimethyl2ergoline 1.38 g aqueous sodium nitrite are added drop-wise with ice-cooling and stirring to 7.8 g of the product of step c) in 220 ml 0.2 N HCI until the pH is ca. 2. When reaction is completed I/Cd paper shows a slight excess of HNO2. The suspension is stirred for a further 30 mins, and added drop-wise to 100 ml 0.4 N, refluxing HCI. A clear solution is obtained which is cooled to room temperature, rendered alkaline with 2N soda solution and filtered. The obtained title compound is taken up in C2H5OH/ethyl acetate (1 : 1), treated with active charcoal, filtered, concentrated and crystallised from methanol. M.P. » 240 ’ C with decomposition.
The 8a-amino-2-methyl-6-n-propyl-ergoline required as starting material for the production of the compounds of examples 25 and 26, may be obtained in conventional manner from the product of step d) above, via demethylation and n-propylation at the 6-position.
EXAMPLE 30; Preparation of 2-bromo-6-n-propyl-8a-p1valoylamino-ergoline 4.6 g pyrrolindonehydropromideperbromide in 100 ml tetrahydrofuran are added drop-wise to 3.1 g 6-n-propyl-8a-p1valoylaminoergoline (see example 2) in 100 ml tetrahydrofuran pre-cooled to 0 * C. After reaction for 2 hours, IN potassium carbonate is -15added and the mixture extracted with methylene chloride. The organic phases are dried over Na2S04, concentrated and the residue chromatographed using 100 g silica gel and toluene/ ethylacetate (2 : 1) as eluant. The title compound is obtained on crystallisation from ethylether/hexane. M.P. 3 182 - 183 * C.
RTAMPLE 31: Preparation of 2-ch1oro-6-n-propy1-8a-pivaloylamino-ergoline g silica gel are added to 2 g 6-n-propyl-8a-pivaloylaminoergol ine (example 2) in 50 ml methylene chloride, pre-cooled to 0 * C. 0.503 ml sulfuryl chloride are added drop-wise and the reaction mixture stirred for 4 hours. IN potassium carbonate solution is added, the mixture extracted with methylene chloride, dried over Na2S04 and concentrated. The residue is chromatographed on 50 g silica gel using toluene/ethylacetate (2 : 1) as eluant to yield the title compound. M.P. 3 146 - 147 ‘ C.
The following compounds of formula I in which Ri 3 H may be prepared analogously to the above examples: EXAMPLE R2 R3 R4 M.P. * C (form) 32 Br CH3 -C(CH3)3 211-212’ (Base) 33 Cl CH3 -CH2-C(CH3)3 192-193’ (Base) 34 Cl CH3 -(CH2)2-CH3 116-117* (Base) EXAMPLE R2 R3 R4 M.P. * C (form) 35 Cl CH3 -CH(CH3)2 141-142* (Base) 36 Br -(CH2)2-CH3 235-237’ (Hydrobromide) 37 Cl -(CH2)2-CH3 213-214’ (Base) RTAHPLE 38: Preparation of l-methyl-6-n-propyl-8a-(2,3-d1hydro-5-benzofuranylami no)-ergoli ne 696 mg finely powdered KOH and 0.77 ml methyl iodide are added to 4.1 g 6-n-propy1-8a-(2,3-d1hydro-5-benzofuranylamino)-ergol1ne (example 9) in 25 ml dimethylsulfoxide. The reactive mixture is stirred for 5 hours, poured onto 150 ml H2O, extracted with ethyl acetate, dried over Na2S04 and concentrated. The residue is chromatographed on 100 g silica gel using methylene chloride/ methanol (98 : 2) as eluant. M.P. * 137 - 138 * C.
The following compounds of the formula I may be prepared analogously: EXAMPLE Rl R2 R3 r4 M.P. * C1 (form) 39 -CH(CH3)2 H -(CH2)2CH3 136-140* (Ϊ Fumarate) 40 -CH(CH3)2 H -(CH2)2CH3 142-143* (Base) 41 -CH(CH3)2 H -(CH2)2CH3 0 /o\och3 ^-<οοη3 n Base. Amorphous powder. See NMR data following. 42 -CH(CH3)2 H -(CH2)2CH3 0 n 158-159* (Base) 43 -C2H5 H -(CH2)2CH3 0 112-115* (Base) 44 -CH(CH3)2 H -(CH2)2CH3 -C(CH3)3 187-188* (Base) 45 -CH(CH3)2 H -(CH2)2CH3 Adamantyl-1 214-215* (Base) 46 -CH(CH3)2 H -(CH2)2CH3 -C(CH3)2-C2H5 192* (Base) 47 -C2H5 CH3 ch3 -c(ch3)3 149-150* (Base) 48 -CH(CH3)2 H ch3 -c(ch3)3 162-163* (Base) EXAMPLE Rl «2 R3 r4 M.P. ’C (form) 49 ch3 H ch3 -c(ch3)3 Base. Amorphors powder - see NMR data following. 50 -ch(ch3)2 H ch3 NHC2H5 191 - 192 (ease) NMR Oata - Compounds of Examples 7, 8, 10, 19, 24, 4l and 49: The following selected, characteristic peaks were observed using NMR spectroscopy, with tetramethyl as reference at 0.0 ppm.
EXAMPLE 7: NMR (CDClj, 90 MHz) .· 0,88 (t, 3H, J ® 7Hz CH -CH -j 2,35 (S, O SK3 ' —3 2 >5 4,65 (m, lH, H-Cg) ; 6,7-7,3 (m, 9H, aroo. H h_<-2* CONH) i 8,0 (broad, 1H, N-H) .
Example 8: 6H, NMR (CDC13, 90 MHz): 0,91 (t, 3H, J - 7HZ, CH^-CH^-); 4,6 (t, 2H, J - 8, -O-CH-)j 4,5 (m, 1H, H-Ca); 6,7-7,8 (ο, 9H, arom. H, H-C2» CONH)» 8,1 (broad, 1H, N-H). -19EXAMPLE 9: NMR (CDC13, 360 MHz): 2,45 (S, 3H, -S-CH3); 6,9-7,6 (m, 9H, arora. 0,9 (t, 3H, J =7Hz, CH3-CH?-); 4,58 (ra, IH, H-C.); o H, H-Cp ; 7,9 (LH, N-H) .
EXAMPLE 10: NMR (CDC13, 90 MHz(: 0,98 (t, 3H, J »7Ηζ, CH^CH^ ; 2,5-3,6 (ra, 9H, H-C? , 8<1θ, H-Cg- H-C 4a* H-Cgeq, N-CH^ 4,55 (m, In, H-Cg); 6,7-7,6 (m, 9H, arom. H, CONH, H-C2); 7,92 (broad, LH, N-H).
EXAMPLE 19: NMR (CDClj. 90 MHZ): 2,4 (S, 3H, CH^C^)» 2,5 (S, 3H, N-CHj); 3,92 (S, 3H, O-CH3); 4,6 (m, LH, Η-Οθ); 6,75-7,55 (m, 6H, arom. H) 7,75 (broad, LH, N-H); 8,L-8,3 (m, LH, arom. H); 8,8-9,0 (m, LH, CCNH> EXAMPLE 24: NMR (CDClg, 90 MHZ): 0,98 (t, 3H, J - 7Hz, CHg-CHp; 2,4 (S, 3H, C2-CH3); 4,6 (m, 1H, H-Cg); 6,8-7,9 (m, 10H, arom. H, N-H, CONH).
EXAMPLE 41: NMR (CDClg. 360 MHZ): 0,97 (t, 3H, J - 7HzCH^-CH2-) j O-CHg); 6,8-7,5 (η, 8H, aroe. H, CONH). -20EXAMPLE 49 NMR (CDCl,, 90 MHZ); 1,2 (S, 9H, t-Butyl); 2,42 (S, 3H, N -CH,); J XI J 3,76 (S, 3H, N^-CH^); 6,68-7,28 (m, 5H, arom.-H, CONH). -21The compounds of formula I and their pharmaceutically acceptable acid addition salts possess pharmacological activity as can be shown in standard animal test methods, and are accordingly indicated for use as pharmaceuticals.
In particular the said compounds and salts possess prolactin (PRL) secretion inhibiting activity as demonstrated e.g. by inhibition of basal prolactin secretion in male rats in the method described by Fllickiger et al, Experienti a 34, 1330 (1970). Compounds of formula I exhibit activity in this test method at dosages of from 0.0005 to 0.5 mg/kg s.c..
In addition compounds of formula I, in particular compounds of formula Ia, and their pharmaceutically acceptable acid addition salts possess leutenising hormone (LH) secretion inhibiting activity as demonstrated by ovulation inhibition in the following test method [c.f. Marko et al., Life Sciences 22» 233 - 240 (1983)]: Female rats (200 - 250 g) of regular 4 day cycle receive test substance during pro-oestrus at ca. 13.00 and 16.00 hrs. The next morning they are sacrificed, the oviducts examined microscopically and the ova counted. Ovulation is deemed to be inhibited only if no ova are found. The average number of ova counted for each of a series of test animal groups receiving test substance at differing dosages is also recorded in order to permit determination of ED50 values i.e. dosages at which 50 % ovulation inhibition 1s achieved. Compounds of formula Ia exhibit activity 1η this test method at dosages of from 0.05 to 10.0 mg/kg i.v..
Furthermore compounds of formula I, 1n particular compounds of formula lb, and their pharmaceutically acceptable acid addition salts, possess apomorphine antagonistic activity as demonstrated -22in the test method described by Janssen et al., Arz. Forsch. 10, 1003, (1960). Thus compounds of formula lb inhibit apormorphine (10 mg/kg s.c.) induced, stereotyped gnawing over periods of several hours, at dosages of from 0.032 mg/kg s.c..
As will be appreciated, activity as PRL secretion inhibitors as demonstrable in the relevant test method described above is also demonstrative of dopamine agonist ac-tivity. Furthermore apomorphine antagonist activity as demonstrable (in particular in respect of compounds of formula lb) in the relevant test method described above is also demonstrable of dopamine antagonist activity. Thus compounds of e.g. formula lb may be characterised as having a dual dopamine agonist/antagonist activity profile. in view of their PRL secretion inhibiting activity, compounds of formula I and their pharmaceutically acceptable acid addition salts are indicated for use as PRL secretion inhibitors, e.g. in the treatment of conditions or disorders for which reduction of prolactin levels is indicated, for example for the treatment of galactorrhoea including post-partum galactorrhoea, for the treatment of prolactin-dependent menstrual disorders including amenorrhea, for the inhibition of lactation including post-partum lactation and morbid lactation as well as for the treatment of hyperprolactinaemic hpyogonadlsm in males and females and of pro25 lactinoma. Furthermore in view of concomitant dopamine agonist activity compounds of formula I and their pharmaceutically acceptable acid addition salts are also Indicated for use as dopamine agonists, e.g. for the treatment of Morbus Parkinson.
In view of their LH secretion inhibiting activity compounds of formula I, in particular compounds of formula Ia, and their pharmaceutically acceptable acid addition salts are further -23indicated for use in the treatment of disorders having an aetiology associated with or modulated by LH secretion or having an aetiology in which the physiological regulation of LH secretion is implicated, for example in the treatment of prostate hyper5 trophy, in the treatment of menopausal syndrome, in particular post-menopausal hot flashes, as well as the treatment of mammaryand prostate-carcinoma.
In view of their apomorphine antagonistic activity compounds of formula I, in particular compounds of formula lb, and their pharmaceutically acceptable acid addition salts are indicated for use as neuroleptic agents, for example for the treatment of schizophrenia.
It will be further be appreciated that where PRL inhibiting activity is accompanied by apomorphine antagonistic activity, e.g. as in the case of compounds of formula lb, and the compounds exhibit a dopamine antagonist profile component, the subject compounds and their pharmaceutically acceptable acid addtion salts will be of particular interest 1n relation to their indicated utility as PRL secretion inhibitors, having regard to the reduced likelihood of undesirable side-effects (e.g. emetic activity) occurring at endocrinologically active dosages.
, For the above uses, the dosage required will of course vary depending on e.g. the particular compound employed, the mode of administration, the particular condition to be treated and the effect desired.
However an indicated daily dosage is in the range of: -241) from about 0.05 to about 5.0 mg for use in PRL secretion inhibition; 2) from about 1 to about 10 mg for use in LH secretion inhibition; and 3) from about 1 to about 40 mg, for neuroleptic use, of compound of formula I, conveniently administered in divided doses of 2 to 4x/day in unit dosage form or in sustained release form. Suitable unit dosage forms accordingly comprise: 1) from about 0.01 to about 2.5 mg; 2) from about 0.25 to about 5.0 mg; and 3) from about 0.25 to about 20.0 mg, (according to intended utility) of compound of formula I together with one or more pharmaceutically acceptable diluents or carriers therefore.
The compounds of formula I may be administered as such or in the form of their pharmaceutically acceptable acid addition salts. Such salts exhibit the same order of activity as the free bases.
The compounds of formula I may be administered by any conventional route, in particular enterally, e.g. orally, for example in the form of tablets or capsules, or parenterally e.g. in the form of 1nject1ble solutions or suspensions.
In accordance with the foregoing the present invention also provides: 1) A pharmaceutical composition comprising a compound of formula I as hereinbefore defined or a pharmaceutically acceptable -25acid addition salt thereof together with a pharmaceutically acceptable diluent or carrier therefor; 2) A compound of formula I as hereinbefore defined or pharmaceutically acceptable acid addition salt thereof for use as a pharmaceutical, i.e. for use in therapy, for example: for use as an PRL secretion inhibitor or for use as a dopamine agonist; or (in particular in the case of compounds of formula I a as hereinbefore defined and their pharmaceutically acceptable acid addition salts) for use as an LH secretion inhibitor; or (in particular in the case of compounds of formula lb as hereinbefore defined and their pharmaceutically acceptable acid addition salts) for use as a neuroleptic; and especially for use in any of the specific indications hereinbefore recited in relation to such use; as well as 3) A method of 3.1. a inhibiting PRL secretion; 3.1. b treating Morbus Parkinson; 3.2 inhibiting LH secretion; or 3.3 effecting neuroleptic treatment, e.g. for treating any of specific conditions hereinbefore recited in relation to such treatment, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I as hereinbefore defined, and in the case of a method as defined under 3.2, in particular a compound of formula Ia as hereinbefore defined, or in the case of a method as defined under 3.3, in particular a compound of formula Ib.as hereinbefore defined, or a pharmaceutically acceptable acid addition salt thereof.

Claims (54)

CLAIMS:
1.A compound of formula I NH-CO-Λ N-R R.-N-*-R (I) wherein Rl is hydrogen or Ci-4alkyl, R
2. Is hydrogen, chlorine, bromine or methyl, r 3 ’ s Ci-salkyl or C3_salkenyl in which the double bond is not at the carbon atom adjacent to the nitrogen atom, and R4 is C3-.7alk.yl; C3-7Cycloalkyl; adamantyl; phenyl; phenyl substituted by one or more members selected from the group consisting of Ci_3alky1, Ci_3alkoxy, Ci_3alkylthio, trifluoromethy, hydroxy, nitro, amino and monoand di-(Ci-3alkyl)-amino; or phenyl bearing a condensed non-aromat1c, heterocyclic ring having 5- or 6-r1ng members Including 1 or 2 hetero atoms selected from the group consisting of oxygen and sulphur, with the proviso that i) when R x and R 2 are both hydrogen and R3 is methyl, R« is other than t.butyl, and ii) when Ri is hydrogen, R 2 is chlorine or methyl and R 3 is methyl, R< is other than t.butyl or acid addition salt thereof. -272. A compound according to claim 1 of formula Ia wherein Rl and R 2 have the meanings given in claim 1, R 3 a is C 2 -5alkyl or C 3 _salkenyl in which the double bond is 15 not at the carbon atom adjacent to the nitrogen atom, and R 4 a is C 3 _7alkyl; C 3 _7cycloalkyl; phenyl; phenyl substituted by one or two members selected from the group consisting of Ci_ 2 alkyl, Ci- 2 alkoxy, Ci_ 2 alkylthio, hydroxy 20 and nitro; or phenyl substituted at two adjacent carbon atoms by a divalent residue of formula -O-CH 2 -O- or -Z-(CH 2 ) n -, wherein Z is oxygen or sulphur and n is 2 or 3, 2 5 or acid addition salt thereof.
3. A compound according to claim 1 of formula lb wherein Rj has the meanings given in claim 1. R2 b is chlorine, bromine or methyl, and R« b is C 3 _ 7 alkyl, C,_7cycloalkyl or adamantyl with the proviso that when Ri is hydrogen, Rj b is chlorine or methyl, R< is other than t.butyl or acid addition salt thereof. A compound of formula I as defined in claim 1, wherein R4 is C3_7alkyl; C3-7Cycloalkyl; adamantyl; phenyl; phenyl substituted by one or two members selected from the group consisting of Cj^alkyl, Ci-3alkoxy, Ci»3a1kylthio, hydroxy.amino and mono- and d1-(Ci_3alkyl)-amino; or phenyl substituted at two adjacent carbon atoms by a divalent residue of formula -O-CH2-O- or -Z-(CH2) n -» wherein Z is oxygen or sulphur and n 1s 2 or 3, or acid addition salt thereof. A compound of formula Ia as defined in claim 2, wherein R 4 a is C3_7alkyl; C3_7cycloalkyl; phenyl; phenyl subsituted by one or two members selected from the group consisting of Ci.2alkyl, C]_2alkoxy, Ci-2alkylth1o and hydroxy; or phenyl substituted at two adjacent carbon atoms by divalent residue of formula -O-CH2-O- or -Z-(CH2)n- wherein Z 1s oxygen or sulphur and n is 2 or 3, or acid addition salt thereof. -296. A compound of claim 1 wherein Ri is H, R 2 is H, R 3 is -(CH 2 ) 2 -CH 3 , R 4 is phenyl. 7 · A compound of claim 1 wherein i -(CH 2 ). 2 -CH 3 , R 4 is -C(CH 3 ) 3 .
4. 8. A compound of claim 1 wherein R^ i 10 R^ is Adamantyl-1.
5. 9. A compound of claim 1 wherein R^ i -(ch 2 ) 2 -ch 3 , r 4 is -C(CH 3 ) 2 -C 2 H 5 . 15
6. 10. A compound of claim -c(ch 2 ) 2 -ch 3 , r 4 is hydrogen, R 2 is H, R 3 is hydrogen, R 2 is H, R 3 is hydrogen, R 2 is H, R 3 is
7. 11. A compound of claim 20 -(CH 2 ) 2 -CH 3 , R 4 is 1 wherein R 1 i ICH3 1 wherein R^ i H3C. H3L· 1 wherein R^ i ,c 7-\
8. 12. A compound of claim 25 -(CH 2 ) 2 -CH 3 , R 4 is hydrogen, R 2 is H, R 3 is hydrogen, R 2 is H, R 3 is hydrogen, R 2 is H, R 3 is -30 13 · A compound of claim 1 wherein R-j -(ch 2 ) 2 -ch 3 , r 4 is SCH 3
9. 14. A compound of claim 1 wherein R-j -(CH 2 ) 2 ~CH 3 , R 4 is |_|Q
10. 15. A compound of claim 1 wherein R^ is hydrogen, R 2 is H, R 3 is is hydrogen, R 2 is H, R 3 is is hydrogen, R 2 is H, R 3 is
11. 16. A compound of claim 1 wherein R 1 -(CH 2 ) 2 -CH 3> R 4 is 0CH 3
12. 17. A compound of claim 1 wherein R-j - ( ch 2 ) 2 -ch 3 , r 4 is _^ 0H is hydrogen, R 2 is H, R 3 is is hydrogen, R 2 is H, R 3 is
13. 18. A compound of claim 1 wherein R^ -(ΟΗρί.-ΟΗ-, R is χ—ι cf 3
14. 19. A compound of claim 1 wherein - 2 ) 2 -ch 3 , r 4 is Aw is hydrogen, R 2 is H, Rj is is hydrogen, R 2 is H, R 3 is -3120. A compound of claim 1 wherein Rj is hydrogen, R^ is H, R^ is - ( ch 2 ) 2 -ch 3 , r 4 is /O/ 0CH 3 '—<0CH3 21 · A compound of claim 1 wherein R^ is hydrogen, R 2 is H, R 3 is .(ch 2 ) 2 ch 3 , R„ is \0/«3 '—<0H
15. 22. A compound of claim 1 wherein is hydrogen, R 2 is H, R 3 is R, is y—< 22 -co^ -0CH3 C2H5
16. 23. A compound of claim 1 wherein R^ is hydrogen, R 2 is CH 3> R 3 is CHp % is CH3O CH 3 , R 4 is
17. 24. A compound of claim 1 wherein R^ is hydrogen, R 2 is CHp R 3 is
18. 25. A compound of claim 1 wherein R^ is hydrogen, R 2 is Η , R 3 is -ch(ch 3 ) 2 , r 4 is -C(CH 3 ) 3 .
19. 26. A compound of claim 1 wherein R. is hydrogen, R~ is CH~, R. is CH-, R 4 is -CH(CH 3 ) 2 .
20. 27. A compound of claim 1 wherein R-j is hydrogen, R 2 is CHp R 3 is CHp R 4 is -C(CH 3 ) 2 ”C 2 Hg.
21. 28. A compound of claim 1 wherein R-j is hydrogen, R 2 is CH 3 , R 3 is CH 3> R 4 is Adamantyl-1. -3229. A compound of claim 1 wherein R^ is hydrogen, R^ is -(CH_)„CH_, R. is —
22. 30· A compound of claim 1 wherein R-j is hydrogen, R? is .-(ch 2 ) 2 ch 3 , ,r 4 is -c(ch 3 ) 3 .
23. 31. A compound of claim 1 wherein R^ is hydrogen, R 2 is CHp is Adamantyl-1.
24. 32. A compound of claim 1 wherein R^ is hydrogen, R 2 is CH 3 , R 4 is -C(CH 3 ) 2 -C 2 H 5 . CH r R, is
25. 33. A compound of claim 1 wherein R^ is hydrogen, R 2 is <2> CH 3 , R 4 is
26. 34. A compound of claim 1 CH 3 , R 4 is -CH(CH 3 ) 2 . wherein R-j is hydrogen, R 2 is CHp R 3 is H, R^ is H, R 3 is H, R.j is H, R 3 is
27. 35. 2-bromo-6-n-propyl-8a-pi valoy1 amino-ergoline.
28. 36. 2-chloro-6-n-propyl-δα-pivaloylami no-ergoli ne.
29. 37. A compound of claim 1 wherein R-| is hydrogen, R 2 is ch 3 , r 4 is -c(ch 3 ) 3 . 3θ· A compound of claim 1 wherein R-j is hydrogen, R 2 is CH 3 , R 4 is -CH 2 -C(CH 3 ) 3 .
30. 39. A compound of claim 1 wherein R-j is hydrogen, R 2 is CH 3 , R 4 is -(CH 2 ) 2 -CH r
31. 40. A compound of claim 1 wherein R·, CH 3 , R 4 is -CH(CH 3 ) 2 .
32. 41. A compound of claim 1 wherein R^ -(ch 2 ) 2 -ch 3 , r 4 is Br, R 3 is Cl, R 3 is Cl, R 3 is Cl, R 3 is Br, Rj is is hydrogen, R ? is is hydrogen, R 2 is -33-(ch 2 ) 2 -ch 3 , R 4 is
33. 42. a compound of claim 1 wherein R^ © is hydrogen, R 2 is Cl, R 3 is
34. 43. 1 -methyl -6-n-propy1-8a-(2,3-di hydro-5-benzo-furany1 ami no)-ergoline.
35. 44. A compound of claim 1 wherein R^ is - CH(CH 3 ) 2> R 2 is H, R 3 is -(CH 2 ) 2 CH 3 , R 4 is
36. 45. A compound of claim 1 wherein R^ is -CH(CH 3 ) 2 , R 2 is H, R 3 is -(CH 2 ) 2 CH 3 , R 4 is
37. 46. A compound -(ch 2 ) 2 ch 3 , r 4 of claim 1 wherein R is <°h och 3 och 3 is -CH(CH 3 ) 2 , R 2 is H, R 3 is
38. 47. A compound of claim 1 wherein R^ is -CH(CH 3 ) 2> R 2 is H, R 3 is -(CH 2 ) 2 CH 3 , R 4 is 0
39. 48. A compound of claim 1 wherein R-j is -C 2 Hg, R 2 is H, R 3 is -(ch 2 ) 2 ch 3 , r 4 is
40. 49. A compound of claim 1 wherein R-j is -CH(CH 3 ) 2 , R 2 is H, R 3 is -(CH 2 ) 2 CH 3 , R 4 is -C(CH 3 ) 3 . -3410
41. 50. A compound of claim 1 wherein -(CH 2 ) 2 CH 3 , is Adamantyl-1.
42. 51. A compound of claim 1 wherein R-j -(ch 2 ) 2 ch 3 , r 4 is -c(Ch 3 ) 2 -c 2 h 5>
43. 52. a compound of claim 1 wherein R^ R 4 is -C(CH 3 ) 3 .
44. 53. A compound of claim 1 wherein R^ CH 3 , R 4 is -C(CH 3 ) 3 .
45. 54. A compound of claim 1 wherein Rj R 4 is -C(CH 3 ) 3 .
46. 55. A compound of claim 1 wherein R ] is -CH(CH 3 ) 2 , R 2 is H, R 3 is is -CH(CH 3 ) 2 , R 2 is H, R 3 is is -C 2 H 5» R 2 1S CH 3’ R 3 1S CH 3* is -CH(CH 3 ) 2> R 2 is H, R 3 is is CHp R 2 is H, R 3 is CH 3> R } is -CH(CH 3 ) 2 , R 2 is H, R 3 is NHC2H5
47. 56. A compound of any one of claims
48. 57. A compound of any one of claims form. 1 to 55 in free base form. 1 to 55 in acid addition salt
49. 58. Process for the production of a compound of formula I as defined in claim 1 or acid addition salt thereof, which process comprises: -35wherein R^, R? and have the meanings given in claim 1, with a compound of formula III R 4 -C00H (III) wherein R^ has the meaing given in claim 1; b) chlorinating or brominating a compound of formula I as defined in claim 1 wherein R^ is hydrogen or produce the corresponding compound of formula I wherein R 2 is chlorine or bromine; or c) N(C.| ^alkylating) a compound of formula I as defined in claim I wherein R-j is hydrogen to produce a corresponding compound of formula I wherein R^ is C-j^alkyl; and recovering the obtained compound of formula I as such or as an acid addition salt thereof.
50. 59. A pharmaceutical composition comprising a compound as defined in any one of the claims 1 to 57 or pharmaceutically acceptable acid addition salt thereof, together with a pharmaceutically acceptable diluent or carrier therefor.
51. 60. A compound as defined in any one of claims 1 to 57 or pharmaceutically acceptable acid addition salt thereof, for use as a pharmaceutical.
52. 61. A compound as defined in any one of claims 1 to 57 or pharmaceutically acceptable acid addition salt thereof, for neuroleptic use. . r ,.
53. 62. A process for the production of a comoound of formula I as defined in claim 1 or acid addition salt thereof substantially as hereinbefore described with reference to the Examples.
54. 63. A compound of formula I, whenever produced by a process according to either of claims 58 or 62.
IE6485A 1984-01-12 1985-01-10 Novel 8 alpha -acylaminoergolines IE58228B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IE358789A IE58241B1 (en) 1984-01-12 1985-01-10 A novel 8 alpha -acylaminoergoline
IE358689A IE58240B1 (en) 1984-01-12 1985-01-10 A novel 8 -acylaminoergoline

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3400853 1984-01-12

Publications (2)

Publication Number Publication Date
IE850064L IE850064L (en) 1985-07-12
IE58228B1 true IE58228B1 (en) 1993-08-11

Family

ID=6224786

Family Applications (1)

Application Number Title Priority Date Filing Date
IE6485A IE58228B1 (en) 1984-01-12 1985-01-10 Novel 8 alpha -acylaminoergolines

Country Status (28)

Country Link
US (2) US4950672A (en)
JP (1) JPH0655739B2 (en)
AT (1) AT391317B (en)
AU (3) AU583489B2 (en)
BE (1) BE901456A (en)
CA (1) CA1245640A (en)
CH (1) CH664568A5 (en)
CY (1) CY1542A (en)
DE (1) DE3500251C2 (en)
DK (1) DK169891B1 (en)
ES (1) ES8605514A1 (en)
FI (1) FI82466C (en)
FR (1) FR2560196B1 (en)
GB (1) GB2152507B (en)
GR (1) GR850065B (en)
HK (1) HK48590A (en)
HU (1) HU197569B (en)
IE (1) IE58228B1 (en)
IL (1) IL74043A (en)
IT (1) IT1214648B (en)
LU (1) LU85725A1 (en)
NL (1) NL193541C (en)
NZ (1) NZ210818A (en)
PH (1) PH23286A (en)
PT (1) PT79818B (en)
SE (1) SE460420B (en)
SG (1) SG32390G (en)
ZA (1) ZA85276B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU197569B (en) * 1984-01-12 1989-04-28 Sandoz Ag Process for producing 8alpha-acylaminoergoline derivatives and pharmaceuticals comprising such compounds
ATE107647T1 (en) * 1984-04-09 1994-07-15 Schering Ag 2-SUBSTITUTED ERGOLINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS.
NL8700046A (en) * 1986-01-24 1987-08-17 Sandoz Ag 8 ALFA-ACYLAMINOERGOLINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
US4981859A (en) * 1987-06-15 1991-01-01 Cycloalkylamides of (8 beta )-1-alkyl-6-(substituted)ergolines
US4931447A (en) * 1987-06-15 1990-06-05 Eli Lilly And Company Cycloalkylamides of (8β)-1-alkyl-6-(substituted) ergolines
IT1219652B (en) * 1987-06-23 1990-05-24 Sandoz Ag 8-ACYLAMINOERGOLINE, ITS PREPARATION AND ITS USE AS A MEDICAMNET
DE3820159A1 (en) * 1987-06-23 1989-01-05 Sandoz Ag 8 alpha -Acylaminoergoline, its preparation and medicaments containing same
DK338789A (en) * 1988-07-15 1990-01-16 Schering Ag 2-SUBSTITUTED ERGOLINYLURINE DERIVATIVES AND PROCEDURES FOR THE PRODUCTION THEREOF, THEIR USE AS MEDICINES AND INTERMEDIATES FOR THE PRODUCTION THEREOF
GB8824744D0 (en) * 1988-10-21 1988-11-30 Erba Carlo Spa Antiemesis ergoline derivatives
DE3915950A1 (en) * 1989-05-12 1990-11-15 Schering Ag 8 (ALPHA) ACYLAMINO ERGOLINE, THEIR PRODUCTION AND USE AS A MEDICINAL PRODUCT
MX2017009406A (en) * 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Isoergoline compounds and uses thereof.
BR112017015487A2 (en) 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc COMPOUND; COMPOSITION; METHOD OF TREATMENT AND / OR PREVENTION OF MIGRAINE, ALS, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, EXTRAPYRIMIDAL DISORDERS, DEPRESSION, NAUSEA, AEMESIS, SYNDROME OF THE WASTE LEGS, INSOMENESS, HYGERNESS, AGING , ANXIETY, DRUG DEPENDENCIES, DYSTONIA, PARASSONIA OR HYPERLACTINEMIA IN AN INDIVIDUAL; AGONIZATION METHODS OF D2, 5-HT1D, 5-HT1A AND 5-HT2C RECEPTORS, IN AN INDIVIDUAL; ANTAGONIZATION METHOD OF THE D3 RECEPTOR IN AN INDIVIDUAL; METHODS OF SELECTIVE AGONIZATION OF RECEPTORS 5 -HT1D, AND 5-HT2C, METHOD OF PROVIDING FUNCTIONAL ANTAGONIST ACTIVITY IN RECEPTOR 5 -HT2B OR IN RECEIVER 5-HT7, OR IN BOTH, IN AN INDIVIDUAL; METHOD OF PROVIDING FUNCTIONAL ANTAGONIST ACTIVITY IN ADRENERGIC RECEPTORS IN AN INDIVIDUAL
BR112019025420A2 (en) 2017-06-01 2020-06-16 Xoc Pharmaceuticals, Inc. POLYCYCLICAL COMPOUNDS AND USES OF THESE

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3218323A (en) * 1965-11-16 Esters of i,g-dimethyl-b-ergolenyl carbamic acid
US2864822A (en) * 1956-10-22 1958-12-16 Lilly Co Eli 9-amino-7-methyl-belta10-ergolene and derivatives thereof
CH622519A5 (en) * 1974-07-05 1981-04-15 Hoechst Ag Process for the preparation of hydroxyalkylxanthines
US4348392A (en) * 1974-07-19 1982-09-07 Sandoz Ltd. 8α-Substituted ergoline-I derivatives
GB1517973A (en) * 1974-07-19 1978-07-19 Sandoz Ltd 6-methyl-8alpha-n,n-dimethylsulphamoylaminoergoline i
US3922347A (en) * 1974-12-19 1975-11-25 Lilly Co Eli Method of inhibiting prolactin secretion with 8-acylaminoergolenes
CH615929A5 (en) * 1975-06-02 1980-02-29 Sandoz Ag Process for the preparation of novel ergoline compounds
DE2656344A1 (en) * 1975-12-23 1977-07-07 Sandoz Ag ERGOLIN DERIVATIVES, THEIR USE AND MANUFACTURING
CH622518A5 (en) * 1976-12-14 1981-04-15 Sandoz Ag Process for the preparation of novel ergoline compounds
CH644606A5 (en) * 1980-09-23 1984-08-15 Sandoz Ag METHOD FOR ISOMERIZING 9,10-DIHYDROLYSE ENERGY DERIVATIVES.
DE3151912A1 (en) * 1981-12-23 1983-06-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen NEW ERGOLIN AMINO DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS
HU197569B (en) * 1984-01-12 1989-04-28 Sandoz Ag Process for producing 8alpha-acylaminoergoline derivatives and pharmaceuticals comprising such compounds
HU195810B (en) * 1984-12-24 1988-07-28 Sandoz Ag Process for preparing new 8alpha-acyl-amino-ergoline derivatives and pharmaceutical compositions containing such compounds
IT1219652B (en) * 1987-06-23 1990-05-24 Sandoz Ag 8-ACYLAMINOERGOLINE, ITS PREPARATION AND ITS USE AS A MEDICAMNET

Also Published As

Publication number Publication date
AU583489B2 (en) 1989-05-04
JPS60174783A (en) 1985-09-09
AT391317B (en) 1990-09-25
FI82466C (en) 1991-03-11
CY1542A (en) 1991-03-22
NL193541C (en) 2000-01-04
NL193541B (en) 1999-09-01
CH664568A5 (en) 1988-03-15
FI850130A0 (en) 1985-01-11
DK12685A (en) 1985-07-13
JPH0655739B2 (en) 1994-07-27
SE8500107D0 (en) 1985-01-10
GB2152507B (en) 1987-07-15
DK169891B1 (en) 1995-03-27
IL74043A0 (en) 1985-04-30
IT1214648B (en) 1990-01-18
PH23286A (en) 1989-06-30
DE3500251A1 (en) 1985-07-18
DE3500251C2 (en) 1995-01-26
ZA85276B (en) 1986-08-27
AU618290B2 (en) 1991-12-19
FI850130L (en) 1985-07-13
AU2506788A (en) 1989-03-02
AU609539B2 (en) 1991-05-02
NZ210818A (en) 1989-02-24
HU197569B (en) 1989-04-28
CA1245640A (en) 1988-11-29
AU3760985A (en) 1985-07-18
LU85725A1 (en) 1985-10-22
IT8547538A0 (en) 1985-01-11
DK12685D0 (en) 1985-01-10
GR850065B (en) 1985-05-03
IE850064L (en) 1985-07-12
SG32390G (en) 1990-08-03
US5077298A (en) 1991-12-31
PT79818A (en) 1985-02-01
FR2560196A1 (en) 1985-08-30
FR2560196B1 (en) 1986-07-18
ATA5985A (en) 1990-03-15
ES539511A0 (en) 1986-03-16
NL8500008A (en) 1985-08-01
HUT37148A (en) 1985-11-28
PT79818B (en) 1987-01-07
SE460420B (en) 1989-10-09
US4950672A (en) 1990-08-21
FI82466B (en) 1990-11-30
HK48590A (en) 1990-06-29
SE8500107L (en) 1985-07-13
IL74043A (en) 1988-10-31
BE901456A (en) 1985-07-08
ES8605514A1 (en) 1986-03-16
GB2152507A (en) 1985-08-07
AU2506688A (en) 1989-02-23
GB8500454D0 (en) 1985-02-13

Similar Documents

Publication Publication Date Title
EP0304019A2 (en) Novel crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid (syn isomer)
IE58228B1 (en) Novel 8 alpha -acylaminoergolines
AU692563B2 (en) Novel pyrrolocarbazoles
EP0070562B1 (en) Ergoline derivatives, processes for their preparation and pharmaceutical compositions containing them
AU635099B2 (en) Quinazoline derivatives and their preparation
US5286726A (en) Difluoroglutamic acid conjugates with folates and anti-folates for the treatment of neoplastic diseases
US5252572A (en) Pyridopyrimidine derivatives, pharmaceutical compositions containing them and process for preparing same
US5066828A (en) Difluoroglutamic acid conjugates with folates and anti-folates for the treatment of neoplastic diseases
US4791115A (en) 2,6-dimethyl-8α-pivaloylamino-9,10-didehydro-ergoline
US4183932A (en) Fused quinazolinones and preparation thereof
EP0009608B1 (en) N-phenethylacetamide compounds, processes for their preparation and therapeutic compositions containing them
GB2151624A (en) Imidazo1 2-cpyrimidine
US4180581A (en) N-9,10-dihydrolysergyl-m-aminobenzoic acid amide derivative
CA1084049A (en) Pyridobenzodiazepinones, processes for their preparation and pharmaceuticals containing them
AU641513B2 (en) 5-isothiazolamine derivatives
US6127362A (en) 9,10-diazatricyclo[4,4,1,12,5 ] decane and 2,7-diazatricyclo [4,4,0,03,8 ] decane derivatives having analgesic activity
CA1122207A (en) Ergot peptide alkaloid derivatives, processes for their preparation and pharmaceutical compositions containing them
IE48442B1 (en) Imidazolylethyl ether derivatives of pyrazolo(3,4-b)pyridine-5-methanols
CA1262545A (en) Imidazo-isoquinoline and imidazo-thienopyridine compounds
KR790001982B1 (en) Process for preparing 1,2,3,4-tetra hydro benzo isoquinolins
US4195086A (en) 6-Branched chain alkyl sustituted ergot alkaloids
EP0240986A2 (en) D-Nor-7-ergoline derivatives, process for preparing them, pharmaceutical composition and use
KR900008564B1 (en) Process for the preparation of novel 8 alpha-acylaminoergolines
IE58240B1 (en) A novel 8 -acylaminoergoline
US4146626A (en) 8-adamantylaminomethyl ergolene derivatives

Legal Events

Date Code Title Description
MM4A Patent lapsed